Nyxoah (NYXH) FDA Approvals $1.57 0.00 (0.00%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$1.56 -0.01 (-0.32%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Nyxoah's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Nyxoah (NYXH). Over the past two years, Nyxoah has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Genio. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Genio FDA Regulatory Events Genio is a drug developed by Nyxoah for the following indication: For the Treatment of Obstructive Sleep Apnea. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement Nyxoah FDA Events - Frequently Asked Questions Has Nyxoah received FDA approval? As of now, Nyxoah (NYXH) has not received any FDA approvals for its therapy in the last two years. What drugs has Nyxoah submitted to the FDA? In the past two years, Nyxoah (NYXH) has reported FDA regulatory activity for Genio. What is the most recent FDA event for Nyxoah? The most recent FDA-related event for Nyxoah occurred on August 8, 2025, involving Genio. The update was categorized as "FDA approved," with the company reporting: "Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65." What conditions do Nyxoah's current drugs treat? Currently, Nyxoah has one therapy (Genio) targeting the following condition: For the Treatment of Obstructive Sleep Apnea. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AgomAb Therapeutics FDA EventsAmylyx Pharmaceuticals FDA EventsCoherus Oncology FDA EventsDiaMedica Therapeutics FDA EventsEntera Bio FDA EventsGalectin Therapeutics FDA EventsGilead Sciences FDA EventsJaguar Animal Health FDA EventsKalaris Therapeutics FDA EventsMicrobot Medical FDA EventsPhathom Pharmaceuticals FDA EventsQuoin Pharmaceuticals FDA EventsSilexion Therapeutics FDA EventsAbbVie FDA EventsTeleflex FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Profound Medical FDA Events Orchestra BioMed FDA Events Sanara MedTech FDA Events KORU Medical Systems FDA Events Apyx Medical FDA Events Microbot Medical FDA Events Avita Medical FDA Events Nano-X Imaging FDA Events Solana FDA Events Inovio Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:NYXH last updated on 8/11/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nyxoah With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement
